Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vistin Pharma ASA ( (DE:VP4) ) just unveiled an update.
Vistin Pharma ASA reported a record year in 2025, achieving all-time high revenue of NOK 452 million and EBITDA of NOK 115 million, driven by a 12% increase in sales volume despite pressure from lower global metformin prices. Fourth-quarter results were solid but slightly below the prior year in revenue and EBITDA, as higher volumes were offset by pricing and product mix effects.
Earnings per share rose 19% to NOK 1.69, underpinned by a strong balance sheet with a 75% equity ratio and a net cash position of NOK 16 million at year-end. Reflecting the robust profitability and cash generation, the board plans to propose an ordinary dividend of up to NOK 1.50 per share for 2025, signaling continued confidence and delivering increased returns to shareholders.
More about Vistin Pharma ASA
Vistin Pharma ASA is a Norwegian pharmaceutical company focused on producing metformin, a widely used treatment for type 2 diabetes. The company targets global markets, and its performance is closely tied to international pricing dynamics and demand for metformin products.
Average Trading Volume: 18,015
Current Market Cap: NOK886.9M
For a thorough assessment of VP4 stock, go to TipRanks’ Stock Analysis page.